Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry

Table 2 Cytotoxicity and antiviral activity of CHLA and PUG against different virus infections ^a

Virus	Cell type	Compounds	CC₅₀(μM)^b	Antiviral effect
				EC₅₀(μM)^c	SI^d
HCMV	HEL	CHLA	306.32 ± 7.00	25.50 ± 1.51	12.01
		PUG	299.32 ± 9.14	16.76 ± 0.88	17.86
HCV	Huh-7.5	CHLA	237.61 ± 4.53	12.16 ± 2.56	19.54
		PUG	222.61 ± 3.41	16.72 ± 2.55	13.31
DENV-2	Vero	CHLA	159.63 ± 7.46	13.11 ± 0.72	12.18
		PUG	151.44 ± 9.31	7.86 ± 0.40	19.27
MV	CHO-SLAM	CHLA	351.83 ± 4.54	34.42 ± 4.35	10.22
		PUG	283.76 ± 11.54	25.49 ± 2.94	11.13
RSV	HEp-2	CHLA	244.17 ± 17.40	0.38 ± 0.05	642.55
		PUG	264.83 ± 23.72	0.54 ± 0.04	490.43
VSV	A549	CHLA	316.87 ± 9.01	61.28 ± 5.50	5.17
		PUG	318.84 ± 4.99	36.98 ± 4.59	8.62
ADV-5	A549	CHLA	316.87 ± 9.01	198.14 ± 14.07	1.60
		PUG	318.84 ± 4.99	196.67 ± 20.05	1.62

^a Values shown are means obtained from three independent experiments with each treatment performed in triplicate.
^b Cytotoxic effects were evaluated by XTT assay to determine the concentration of 50% cellular cytotoxicity (CC₅₀) of the tested compounds.
^c Antiviral effects were evaluated by infection analysis to determine the effective concentration that achieved 50% inhibition (EC₅₀) against the specific virus examined.
^d SI, selectivity index. SI = CC₅₀/EC₅₀.

ISSN: 1471-2180